Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

BACKGROUND: Among interleukin-6 inhibitors suggested for use in COVID-19, there are few robust evidences for the efficacy of sarilumab. Herein, we evaluated the efficacy and safety of sarilumab in severe COVID-19. METHODS: In this phase 3, open-labeled, randomized clinical trial, conducted at 5 Ital...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastrorosa, Ilaria, Gagliardini, Roberta, Segala, Francesco Vladimiro, Mondi, Annalisa, Lorenzini, Patrizia, Cerva, Carlotta, Taddei, Eleonora, Bai, Francesca, Vergori, Alessandra, Marcantonio, Negri, Pinnetti, Carmela, Cicalini, Stefania, Murri, Rita, Mazzotta, Valentina, Camici, Marta, Mosti, Silvia, Bini, Teresa, Maffongelli, Gaetano, Beccacece, Alessia, Milozzi, Eugenia, Iannetta, Marco, Lamonica, Silvia, Fusto, Marisa, Plazzi, Maria Maddalena, Ottou, Sandrine, Lichtner, Miriam, Fantoni, Massimo, Andreoni, Massimo, Sarmati, Loredana, Cauda, Roberto, Girardi, Enrico, Nicastri, Emanuele, D'Arminio Monforte, Antonella, Palmieri, Fabrizio, Cingolani, Antonella, Vaia, Francesco, Antinori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999914/
https://www.ncbi.nlm.nih.gov/pubmed/36936403
http://dx.doi.org/10.1016/j.eclinm.2023.101895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999914/
https://www.ncbi.nlm.nih.gov/pubmed/36936403
http://dx.doi.org/10.1016/j.eclinm.2023.101895

Ejemplares similares